Eriglip M 500mg/20mg Tablet is a combination oral antidiabetic medication containing Metformin hydrochloride 500mg and Teneligliptin 20mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control without causing significant hypoglycemia. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of incretin hormones such as GLP-1 and GIP, leading to increased insulin secretion and decreased glucagon release in a glucose-dependent manner. The combination of these two agents provides complementary mechanisms to improve glycemic parameters effectively. Eriglip M is typically prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or combination therapy. It is important to monitor renal function prior to and during therapy, given Metformin’s contraindications in renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Teneligliptin is generally well tolerated. Dose adjustments should be individualized based on clinical response and tolerability. This combination should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.